The evaluation of HER2 bright-field ISH is traditionally performed under an optical microscope by visually counting black and red dots in at least 20 cells in two separate areas of invasive cancer, which is time-consuming, laborious, and tedious and suffers from interobserver variability [6, 12–14]. Here, ERBB2 is linked to cancer.